The effects of tirzepatide on the body share many similarities with semaglutide
Tirzepatide provides continuous receptor activation at levels far exceeding physiological GLP-1 concentrations
In Europa esiste quindi gi un farmaco specificamente autorizzato per la MASH
We did [look at which GLP-1 agonist the patients received]
We gathered GWAS summary-level data for 12 common types of psychiatric disorder, including schizophrenia, anxiety disorders, bipolar disorder, bulimia nervosa, PTSD, autism, OCD, anorexia nervosa, broad depression, MDD, and suicide or other intentional self-harm, from large-scale consortia
This targeted response reduces the risk of low blood sugar (hypoglycemia), promoting steadier glucose control and improved overall metabolic health